Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to TACE By Ogkologos - January 15, 2025 954 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMERALD-1 and LEAP-012 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of... March 26, 2026 Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia April 18, 2023 Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... October 15, 2021 Load more HOT NEWS Preparing for your COVID-19 Vaccine: What to Ask your Provider The Future Front Line: Pre-Med During COVID-19 Body Location May Influence Fate of Cells with Cancer-Causing Mutations McDonald’s Customer Buys Breakfast For Mom And Soldier Son, Unaware Of...
